NASDAQ:MORF Morphic (MORF) Stock Price, News & Analysis $56.55 -0.06 (-0.11%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$56.52▼$56.6450-Day Range$26.12▼$56.6152-Week Range$19.34▼$62.08Volume1.41 million shsAverage Volume1.21 million shsMarket Capitalization$2.83 billionP/E RatioN/ADividend YieldN/APrice Target$54.25 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Morphic alerts: Email Address Morphic MarketRank™ Stock AnalysisAnalyst RatingHold2.29 Rating ScoreUpside/Downside4.1% Downside$54.25 Price TargetShort InterestHealthy3.35% of Shares Sold ShortDividend StrengthN/ASustainability-0.57Upright™ Environmental ScoreNews Sentiment0.27Based on 14 Articles This WeekInsider TradingSelling Shares$7.02 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($4.07) to ($4.47) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.66 out of 5 starsMedical Sector274th out of 936 stocksPharmaceutical Preparations Industry123rd out of 436 stocks 1.1 Analyst's Opinion Consensus RatingMorphic has received a consensus rating of Hold. The company's average rating score is 2.29, and is based on 2 buy ratings, 5 hold ratings, and no sell ratings.Amount of Analyst CoverageMorphic has only been the subject of 4 research reports in the past 90 days.Read more about Morphic's stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted3.35% of the outstanding shares of Morphic have been sold short.Short Interest Ratio / Days to CoverMorphic has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Morphic has recently decreased by 71.81%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldMorphic does not currently pay a dividend.Dividend GrowthMorphic does not have a long track record of dividend growth. Previous Next 4.8 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreMorphic has received a 76.58% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Preclinical research services for physical health" and "Clinical research services for physiological diseases " products. See details.Environmental SustainabilityThe Environmental Impact score for Morphic is -0.57. Previous Next 2.9 News and Social Media Coverage News SentimentMorphic has a news sentiment score of 0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 14 news articles for Morphic this week, compared to 3 articles on an average week.Search Interest6 people have searched for MORF on MarketBeat in the last 30 days. This is an increase of 500% compared to the previous 30 days.MarketBeat Follows3 people have added Morphic to their MarketBeat watchlist in the last 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Morphic insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $7,018,566.00 in company stock.Percentage Held by Insiders25.60% of the stock of Morphic is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions94.25% of the stock of Morphic is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Morphic's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Morphic are expected to decrease in the coming year, from ($4.07) to ($4.47) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Morphic is -16.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Morphic is -16.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMorphic has a P/B Ratio of 4.04. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Morphic's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. About Morphic Stock (NASDAQ:MORF)Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, and metabolic diseases, as well as fibrosis and cancer. Its lead product candidate MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation is in Phase 2 clinical trials for the treatment of inflammatory bowel disease. The company's products in pipeline include Next Gen a4ß7 Inhibitors for additional potential GI indications, such as EGIDs, pouchitis, etc.; avß8 for the treatment of Myelofibrosis and solid tumor; and fibronectin integrin for pulmonary hypertensive. In addition, it has a license agreement with Janssen to discover and develop novel integrin therapeutics; collaboration agreement with Schrödinger for integrin targets; and license agreement with Children's Medical Center Corporation to develop and commercialize products worldwide for any therapeutic or diagnostic use in humans and veterinary applications. Morphic Holding, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.Read More MORF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MORF Stock News HeadlinesJuly 11, 2024 | insidertrades.comInsider Selling: Morphic Holding, Inc. (NASDAQ:MORF) General Counsel Sells 10,000 Shares of StockJuly 8, 2024 | marketbeat.comMorphic Holding, Boeing rise; Paramount, Devon Energy fall, Monday, 7/8/2024Stocks that are trading heavily or have substantial price changes on Monday:July 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.July 26 at 12:40 PM | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Morphic Holding (MORF), Pyxis Oncology (PYXS) and Zynex (ZYXI)July 25 at 5:26 PM | stockhouse.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MORF, AGR, SHCR, DRQ on Behalf of ShareholdersJuly 23 at 4:27 PM | prnewswire.comSHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates Merger of Morphic Holding, Inc. - MORFJuly 23 at 6:50 AM | americanbankingnews.comMorphic (NASDAQ:MORF) Price Target Raised to $57.00 at Stifel NicolausJuly 22, 2024 | markets.businessinsider.comStifel Nicolaus Keeps Their Hold Rating on Morphic Holding (MORF)July 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.July 20, 2024 | globenewswire.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SHCR, MORF on Behalf of ShareholdersJuly 19, 2024 | globenewswire.comSHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates Merger of Morphic Holding, Inc. – MORFJuly 11, 2024 | globenewswire.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SPR, MORF on Behalf of ShareholdersJuly 9, 2024 | prnewswire.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MORF, DM on Behalf of ShareholdersJuly 9, 2024 | seekingalpha.comWhat Eli Lilly Is Getting With The Acquisition Of Morphic HoldingJuly 8, 2024 | prnewswire.comShareholder Alert: Ademi LLP investigates whether Morphic Holding, Inc. has obtained a Fair Price for its Public ShareholdersJuly 8, 2024 | investorplace.comWhy Is Morphic (MORF) Stock Up 75% Today?July 8, 2024 | globenewswire.comMORF Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Morphic Holding to Eli LillyJuly 8, 2024 | reuters.comEli Lilly to acquire Morphic Holding for $3.2 billionSee More Headlines Receive MORF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Morphic and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/04/2021Today7/26/2024Next Earnings (Estimated)11/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:MORF CUSIPN/A CIK1679363 Webwww.morphictx.com Phone(781) 996-0955FaxN/AEmployees100Year FoundedN/APrice Target and Rating Average Stock Price Target$54.25 High Stock Price Target$57.00 Low Stock Price Target$46.00 Potential Upside/Downside-4.1%Consensus RatingHold Rating Score (0-4)2.29 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($3.50) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-152,100,000.00 Net MarginsN/A Pretax Margin-29,119.96% Return on Equity-22.93% Return on Assets-22.26% Debt Debt-to-Equity RatioN/A Current Ratio38.17 Quick Ratio38.17 Sales & Book Value Annual Sales$520,000.00 Price / Sales5,447.29 Cash FlowN/A Price / Cash FlowN/A Book Value$14.01 per share Price / Book4.04Miscellaneous Outstanding Shares50,090,000Free Float37,270,000Market Cap$2.83 billion OptionableOptionable Beta1.50 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesDr. Bruce N. Rogers Ph.D. (Age 55)President & Interim Principal Executive Officer Comp: $787.88kDr. Timothy A. Springer Ph.D. (Age 76)Founder, Independent Director & Member of Scientific Advisory Board Comp: $40kDr. Marc Schegerin M.B.A. (Age 48)M.D., CFO & COO Comp: $722.38kDr. Praveen P. Tipirneni M.D. (Age 55)CEO, MD & Director (Leave of Absence) Comp: $991.33kMr. Robert E. Farrell Jr. (Age 59)CPA, Senior VP of Finance & Chief Accounting Officer Dr. Blaise Lippa Ph.D.Chief Scientific OfficerMr. William D. DeVaul Esq. (Age 53)General Counsel & Secretary Comp: $601.44kMr. Aaron PeltaSenior Vice President of Business & Corporate DevelopmentMs. Joanne GibbonsSenior Vice President of Regulatory AffairsDr. Simon Cooper MBBS (Age 54)Chief Medical Officer More ExecutivesKey CompetitorsRedHill BiopharmaNASDAQ:RDHLCatalentNYSE:CTLTQiagenNYSE:QGENRoivant SciencesNASDAQ:ROIVLantheusNASDAQ:LNTHView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 27,480 shares on 7/26/2024Ownership: 0.304%Assenagon Asset Management S.A.Bought 17,578 shares on 7/18/2024Ownership: 0.178%SG Americas Securities LLCBought 8,691 shares on 7/12/2024Ownership: 0.017%Bruce RogersSold 20,000 sharesTotal: $1.12 M ($55.79/share)Praveen P TipirneniSold 21,582 sharesTotal: $1.20 M ($55.79/share)View All Insider TransactionsView All Institutional Transactions MORF Stock Analysis - Frequently Asked Questions How have MORF shares performed this year? Morphic's stock was trading at $28.88 at the beginning of 2024. Since then, MORF shares have increased by 95.8% and is now trading at $56.55. View the best growth stocks for 2024 here. How were Morphic's earnings last quarter? Morphic Holding, Inc. (NASDAQ:MORF) announced its earnings results on Thursday, November, 4th. The company reported ($0.69) EPS for the quarter, beating the consensus estimate of ($0.73) by $0.04. The business's quarterly revenue was down 88.0% on a year-over-year basis. When did Morphic IPO? Morphic (MORF) raised $75 million in an initial public offering (IPO) on Thursday, June 27th 2019. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Jefferies, Cowen, BMO Capital Markets and Wells Fargo Securities acted as the underwriters for the IPO. Who are Morphic's major shareholders? Top institutional shareholders of Morphic include Bank of New York Mellon Corp (0.30%), Assenagon Asset Management S.A. (0.18%), SG Americas Securities LLC (0.02%) and DNB Asset Management AS (0.01%). Insiders that own company stock include Timothy A Springer, Bruce Rogers, Praveen P Tipirneni, Marc Schegerin, William Devaul, Robert E Farrell, Jr, Robert E Farrell Jr, Joseph P Slattery and Peter Linde. View institutional ownership trends. How do I buy shares of Morphic? Shares of MORF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Morphic own? Based on aggregate information from My MarketBeat watchlists, some other companies that Morphic investors own include Fulcrum Therapeutics (FULC), Akero Therapeutics (AKRO), AVEO Pharmaceuticals (AVEO), Atreca (BCEL), CymaBay Therapeutics (CBAY), Chiasma (CHMA) and Clovis Oncology (CLVS). This page (NASDAQ:MORF) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Morphic Holding, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Morphic With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
